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Abstract: Identiﬁ  cation of correlation pattern and signal pathway among biomarkers in patients has become increasingly 
interesting for its potential values in diagnosis, treatment and prognosis. EGFR and p-AKT signaling in osteosarcoma (OS) 
patients were analyzed for its relationship with cancer cell proliferation maker, Ki-67, using causal procedures and statisti-
cal tests. A total of 69 patients were collected who present to Vanderbilt University Medical Center with newly diagnosed, 
previously untreated osteosarcomas during the clinical study period 1994 through 2003. Tissue microarrays were constructed 
for EGFR, p-AKT and Ki-67. The mediation model was constructed with structural equation model (SEM) for the causal 
analysis of the three biomarkers in osteosarcoma patients. The results suggested a mediating effect of p-AKT for the causal 
relationship between EGFR and Ki-67. The study also found signiﬁ  cant associations between EGFR and Ki-67 (p = 0.002), 
EGFR and p-AKT (p = 0.027), and p-AKT and Ki-67 controlling EGFR (p = 0.004). After the impact of EGFR on Ki-67 
was accounted for by p-AKT, the relation between EGFR and Ki-67 was no longer signiﬁ  cant (p = 0.381). The mediating 
effect was conﬁ  rmed with Sobel test (p  0.001) and Goodman (I) test (p  0.001). The study indicated that a mediation 
model could be an approach to exploring the correlation pattern of EGFR and AKT signal pathway for cancer cell prolif-
eration in OS patients in clinical study.  
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Introduction
Osteosarcoma (OS) is the most common primary bone sarcoma with approximately 900 new cases in 
the United States each year. Although chemotherapy and surgery have improved survival, 5-year survival 
has reached a plateau of approximately 70% and this ﬁ  gure has not changed signiﬁ  cantly for almost 20 
years (Ferguson and Goorin, 2001). New treatments, especially those that may target speciﬁ  c cellular 
pathway components, are of particular interest (Anninga et al. 2004; Hughes et al. 2004). Among these 
components, epidermal growth factor receptor (EGFR), a membrane protein, has been well studied for 
its function in cancer biology. EGFR has been found to be expressed in a variety of human tumors of 
epithelial origin including lung, breast, colorectal, pancreatic, ovarian (Arteaga, 2002; Tabernero et al. 
2004) as well as OS (Dobashi et al. 2004; Hughes et al. 2004). Activation of EGFR causes increased 
cell proliferation, decreased apoptosis, and enhanced tumor cell motility and neo-angiogenesis. All 
these events are mediated by a sequence of proteins including phosphatidylinositol-3 kinase (PI3K) 
and protein kinase B (AKT). AKT acts downstream of PI3K to regulate many biological processes, 
ultimately resulting in a cascade of cellular responses and events such as survival, proliferation, and 
cell growth (Tabernero et al. 2004; Vivanco and Sawyers, 2002; Xia et al. 2002). Studies have already 
shown that the inhibition of AKT blocked the EGFR-initiated transformation of the cells (Lan et al. 
2000; Vivanco and Sawyers, 2002) . However, studies of the association between EGFR and cancer 
development in OS patients are few. Previous studies of the role of EGFR in OS involved relatively 
small numbers of cases (Dobashi et al. 2004; Hughes et al. 2004). In addition, no reports are available 
on the correlation pattern among EGFR, AKT, and Ki-67, a cancer cell proliferation index.
Mediation model may be an approach to looking at the correlation pattern among the biomarkers 
with its causal hypothesis (MacKinnon et al. 1995; MacKinnon, 1993). Usually, bi-variate correlation 
models can be applied to address the relationship between an explanatory variable and an outcome. But 
these models are unlikely to describe adequately the nature of the relationships among the related vari-
ables, such as the three biomarkers in the present study. An alternative approach is to use more complex 470
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path analysis models such as mediation model. 
These more complex explanatory models could 
yield important information about the nature of the 
relationships (Beck, 2004).  Mediation model was 
designed to analyze a causal hypothesis whereby 
an independent variable causes a mediator which 
causes a dependent variable. A variable may be 
considered a mediator (M) to the extent to which 
it carries the inﬂ  uence of a given independent vari-
able (X) to a given dependent variable (Y). Media-
tion can be said to occur when (1) X signiﬁ  cantly 
affects M, (2) X significantly affects Y in the 
absence of M, (3) M has a signiﬁ  cant effect on Y 
in the presence of X, and (4) the effect of X on Y 
shrinks upon the inclusion of the M in the model. 
The mediation effect can also be tested with some 
appropriate statistical procedures (MacKinnon 
et al. 1995; MacKinnon, 1993).  
The focus of the present study is to answer 
whether the expression of EGFR and AKT corre-
lated with the cancer cell proliferation and how the 
three biomarkers were correlated in OS patients 
by using a mediation model with an interest in 
exploring its value in treatment, diagnosis and 
prognosis.
Materials and Methods 
Patients 
Patients were identiﬁ  ed by searching through the 
pathology database which contained pathological 
results for those who present to Vanderbilt Univer-
sity Medical Center from 1994 through 2003 with 
newly diagnosed, previously untreated OS. The 
Institutional Review Board of Vanderbilt Medical 
School reviewed and approved the study. All the 
patients completed one course of chemotherapy 
prior to resection of their tumors. The informed 
consent was waived. Slides and archival tissue 
blocks from these patients’ resections were 
retrieved. Two pathologists experienced in the 
diagnosis of bone tumors reviewed all the diag-
nostic slides and classiﬁ  ed these tumors according 
to the World Health Organization (WHO) classiﬁ  -
cation of tumors. One hundred OS patients 
reviewed were categorized as conventional OS 
including the three main histologic subtypes of 
conventional OS: osteoblastic, chondroblastic, and 
ﬁ  broblastic subtypes. Excluded in the analysis were 
other rare osteosarcoma subtypes including small 
cell OS, parosteal OS, periosteal OS, high grade 
surface OS, NOS, and low grade intramedullary 
OS, resulting in a total of 69 subjects for the 
analysis. Clinical data gathered for these patients 
included date of biopsy or resection, presence of 
local recurrence, presence of metastasis, and last 
date of follow-up. Demographic information of the 
patients was also collected in this study.  
Tissue microarray
and immunostaining 
Three tissue microarrays (TMAs) were constructed 
from one representative 1mm punch taken from 
parafﬁ  n-embedded tissue blocks of each tumor. 
Paraffin immunoperoxidase studies were per-
formed with a monoclonal antibody against total 
EGFR (Zymed, prediluted antibody, Cat. No. 08-
4205) and a monoclonal antibody against phos-
phorylated AKT (p-AKT, Cell Signaling). All 
TMAs were immunostained for the proliferation 
marker Ki-67 (Dako, MIB-1). 
For EGFR and p-AKT, expression was scored 
as index (index = intensity of staining × % tumor 
cells staining). Ki-67 nuclear immunostaining was 
evaluated as an estimated percentage of positive 
tumor cells. Membrane staining was evaluated for 
EGFR whereas both nuclear and cytoplasmic stains 
were noted for p-AKT.  In statistical analysis, we 
used nuclear score of p-AKT.  
Statistical analysis
Two approaches were taken to analyze mediating 
effect; one was causal analysis and the other was 
statistical test. For causal analysis, we built three 
models to identify the mediating effect. Model (1) 
is illustrated by Figure 1 in which we look for a 
signiﬁ  cant association between X and Y, i.e. (τ). 
 Y  = β 0(1) + τ X + ε1 (1) 
Model (2) and (3) are illustrated by Figure 2 in 
which the effect of X on Y goes through M. The 
parameter α in Model (3) relates X to M, whereas 
parameter β in Model (2) relates the mediator to 
the outcome. In these two models we look for 
signiﬁ  cant α and β, and insigniﬁ  cant τ'. 
 Y  = β 0(2) + τ' X + βM + ε2   (2) 
 M  = β 0(3) + α X + ε3 (3) 471
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From the three models, we have (MacKinnon 
et al. 2000):
Direct effect = τ′
Mediated effect = α β
Total effect = τ
For the statistical tests, we ran Sobel test (Sobel, 
1982), which basically tests the null hypothesis 
that the indirect effect  (product of α and β ) is zero 
in the population from which the sample data are 
randomly drawn. The test statistics is computed by 
dividing the indirect coefﬁ  cient by its standard 
error.
Sobel test:
 Z-value  =  αβ α β
22 22
βα ∗/ σ+  σ   
Goodman (I) test:
 Z-value  = αβα β α
22 22 22
βα α β ∗/ σ+  σ+ σ 
We also performed Goodman (I) version of Sobel 
test according to the recommendation (MacKinnon 
et al. 1995). The test has slightly different standard 
error term and it also avoids unnecessary assumption 
that the product of σα and σβ is too small.
The three causal models were constructed and 
implemented with structural equation model 
(SEM), which computed the three models simul-
taneously. The SEM also adjusted for age and sex 
(Fig. 3). A bootstrap procedure was incorporated 
to the computations considering the small sample 
size and non-normal data distribution as recom-
mended (MacKinnon, 2004; Shrout and Bolger, 
2002). In addition to Sobel test and Goodman test 
with formula developed by Mackinnon and Dwyer 
(MacKinnon et al. 1995; MacKinnon, 1993), the 
mediating effect was also tested using spline 
regression that allows for ﬂ  exible relationship 
among the three variables. In our study, we used 3 
knots in spline regression model for the small 
sample size, which generated two degree of free-
dom test with two coefﬁ  cients (two αs and two 
βs). Instead of performing multiple tests for α*β, 
we ran the test for a mediation of overall effects of 
α and overall effects of β by using F statistics. To 
have a general view of the data distribution, three 
scatter-plots were made for predictive biomarker 
and dependent biomarker. The plots were also 
Figure 1. Path for Model 1. A two-variable correlation model between an explanatory variable and an outcome variable. τ is the parameter 
of interest. ε is the error term.  
Figure 2. Paths for Model 2 and Model 3. A three-variable mediation model. X, M, and Y are symbols of the three variables. α, β and τ′ are 
the parameters of interest. ε is the error term.  472
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overlapped with curves estimated using a nonpara-
metric smoother. The package of AMOS 5.0 
(SPSS, Chicago, IL) was used for mediation mod-
eling and R version 2.2.0 ((http://cran.r-project.
org/) for the spline regression. The interactive 
calculation tool at http://www.unc.edu/~preacher/
sobel/sobel.htm was employed for Sobel test and 
Goodman test. All the p values were two-tailed 
with statistical signiﬁ  cance at p  0.05. 
Results 
The immunostaining of EGFR and p-AKT were 
shown in Figure 4. The characteristic of the patients 
EGFR
p-AKT
Ki-67
0, 1
e2
0, 1
e1
0, 1
d1
Age gender
Figure 3. Structural equation modeling for mediation effect. Dependent variable Ki-67 is predicted with single-headed EGFR and p-AKT. 
Each single-headed arrow represents a regression weights. Age and gender are considered to be associated with all the three biomarkers 
and are also allowed to be correlated and represented with double-headed arrow. Circles of e1, e2 and d1 are error terms with mean at 0 
and variance at 1.
Figure 4. Expression of EGFR and p-AKT. Left panel: membrane staining in tumor cells with EGFR; right panel: nuclear and cytoplasmic 
staining in tumor cells with p-AKT.473
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and provided a new avenue to cancer treatment 
(Curtis et al. 2005; Mao et al. 2006). However, the 
available analysis approaches and tools are limited, 
and no much effort has been made to look for the 
signal pathways in population study. The concept 
and application of medication model have been 
seen in social science, behavioral science, and 
preventive medicine. Mediation model analyzes 
“how” an effect occurs by hypothesizing a causal 
sequence (MacKinnon, 1993). In practice, media-
tion is the mechanism by which a variable affects 
another variable. Interestingly, signaling events are 
ordered both spatially and temporally, and the 
processes of signal transduction in cells are also in 
causal steps.  
Our study found  a significant association 
between EFGR expression and proliferation 
marker Ki-67 (τ in Model 1), supporting the ﬁ  nd-
ings from biological studies (Anninga et al. 2004; 
Arteaga, 2002). This result suggested an involve-
ment of EGFR in OS development. In studies of 
patient survival, EGFR has been identiﬁ  ed as a 
strong prognostic indicator in a wide range of 
tumors (Gorlick et al. 1999; Magne et al. 2001; 
Neskovic-Konstantinovic et al. 1999; Tsutsui et al. 
2002). Our study also indicated that EGFR was a 
signiﬁ  cant predictor of p-AKT (α in Model 3). 
Biological experiments have demonstrated that the 
activation of EGFR was the essential upstream 
event for AKT to function and cause its down-
stream events (Arteaga, 2002; Lan et al. 2000). 
According to Model (2), the present study clearly 
showed that the association between X and Y was 
remarkably attenuated and no longer signiﬁ  cant 
after M was controlled (τ') while M was also a 
signiﬁ  cant predictor of Y in the same model. Trans-
lated into biology, the ﬁ  ndings said that once p-
AKT was introduced in the analysis of the 
relationship between EGFR and Ki-67, the impact 
of EGFR on Ki-67 was carried by p-AKT which 
was also significantly associated with Ki-67. 
Experiments have been conducted and shown that 
p-AKT was up-regulated upon the activation of 
EGFR and it mediated the signal from EGFR to 
cancer cell proliferation (Lan et al. 2000; Vivanco 
and Sawyers, 2002). In a clinical study of EGFR 
tyrosine kinase inhibitor (erlotinib) on malignant 
gliomas patients, AKT activation status was found 
to determine the response of the tissue to the 
inhibitor (Haas-Kogan et al. 2005), suggesting  that 
p-AKT had mediated EGFR signaling in the 
patients.
Table 1. Characteristic of the patients (N = 69).
Characteristic   Measurement 
Age (mean ± SD)  28.9 ± 15.6 
Female (%)  33 (48%) 
Diagnosis (%) 
  osteoblastic   49 (71%) 
  chondroblastic   7 (10%)
  ﬁ  broblastic   5 (7%) 
  other   8 (12%)
Recurrence (%)
1 31  (48) 
Metastasis (%)
2 33  (49)
1Three patients had missing values. 
2Two patients had missing values.
were listed in Table 1. The age distribution in OS 
patients was bi-model, one occurring in the second 
decade of life and the other over forty with an 
average of 29 years. The patients were 47% female. 
The major tumor subtype was osteoblastic (71%).   
The marginal relations between predictive bio-
marker and dependent biomarker indicated a 
positive trend for all the three relationships with 
the one between p-AKT and Ki-67 more linear 
(Fig. 5). 
The results from the 3 causal models were sum-
marized in Table 2. A signiﬁ  cant association was 
found between EGFR and Ki-67(p = 0.002,τ). 
EGFR was a significant predictor for p-AKT 
(p = 0.027, α), which in turn was a signiﬁ  cant 
predictor for Ki-67 controlling EGFR (p = 0.004, 
β ). After p-AKT was taken into account, the rela-
tion between EGFR and Ki-67 was no longer 
signiﬁ  cant (p = 0.381, τ'), suggesting a mediating 
effect of p-AKT on the proposed causal relation 
between EGFR and Ki-67 in OS patients. As 
detailed in Table 2, the total effect of EGFR on 
Ki-67 was 0.038, and the mediated effect of 0.029 
accounted for 76% of the total effect.
Sobel test and Goodman (I) test conﬁ  rmed a 
significant indirect effect of α*β (p < 0.001) 
(Table 3), supporting the results from the causal 
analysis. The results of the two statistical tests with 
spline regression remained signiﬁ  cant (Table 3).
Discussion 
Correlations among biomarkers and signal pathway 
analysis have been becoming increasingly interest-
ing in cancer biology and drug research and devel-
opment. Identiﬁ  cation of biomarker correlation 
pattern and signal pathways has shed light in elu-
cidating the mechanisms of cancer development 474
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in all the predictors (Harrell Jr., 2001). Our study 
dealt with this issue by using spline regression that 
allows for nonlinear relationship. Two coefﬁ  cients 
were computed in spline regression with knots = 3 
in our study.  In stead of performing multiple tests 
for α*β = 0, we tested mediation for overall effects 
of α and overall effects of β by applying F statistics 
to the Sobel test and Goodman test. Similar results 
were obtained with the spline regression, conﬁ  rm-
ing the mediating effect of p-AKT in the path.  
Confounding effect is a common issue in mul-
tiple regression analysis with distinguished proper-
ties. In concept, mediation is part of the causal 
chain, whereas confounding is a cause of the 
Figure 5. Scatter plots with lowess lines. Circles are data points and lines are the lowess smoothing lines. 
In addition to the causal analysis, Sobel test and 
Goodman test also indicated a mediating effect of 
p-AKT for EGFR signaling to Ki-67 in the patients. 
These test results were formal statistical evidence 
for the mediation (MacKinnon, 1993). Thus, both 
causal procedures and statistical tests strongly sug-
gested that the associations among EGFR, p-AKT 
and Ki-67 in the OS patients fell into a mediation 
pattern.  
SEM was used in the study because of its advan-
tage in joint modeling. A concern on using SEM 
is that it assumes linear relationship that may not 
be necessarily plausible in biology. In many cases, 
the property of outcome does not behave linearly 475
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outcome and correlated with the independent vari-
able. Confounding differs from mediating in that 
confounding explains the relationship between X 
and Y whereas mediating carries the relationship 
between X and Y (Robins, 1989). Confounding 
does not imply a causal relationship among the 
three variables, thus there is no indirect effect from 
X to Y. Unlike mediating effect, confounding effect 
can’t be statistically tested (MacKinnon et al. 
2000). Interaction is another issue in multivariate 
analysis. The difference between interaction and 
mediation is subtle. Interaction test is basically to 
test the product of the two exposure variables = 0 
with relation to the outcome variable using either 
likelihood ratio test or Wald test whereas mediation 
test is to test the net effect of α*β = 0 (or α-β = 0) 
with Sobel test or other tests. Interaction test tells 
whether the effect of X on Y is modiﬁ  ed at different 
levels of the third variable; however, mediation 
test tells us whether the effect of X on Y is changed 
with or without the third variable. In interaction, 
the two variables are both independent variables. 
But in mediation, the mediator is both a dependent 
variable relative to X and an independent variable 
relative to the outcome. Interaction and mediation 
may coexist, but their exact analytical procedures 
in this case have not been completely articulated 
(Muller et al. 2005). Interaction has no causality 
and thus interaction does not imply mediation. 
Although the causal analysis and statistical test 
suggested a mediated effect of EGFR to Ki-67 by 
p-AKT, the study was limited by the cross-sectional 
nature which raised a concern on the causal 
assumption. Nevertheless, the biological studies 
that signaling events are ordered temporally and 
spatially have conditioned our models still in a 
follow-up pattern, however conceptually. In fact, 
the mediation model has been used  in many other 
cross-sectional studies (Beck et al. 2005; Frone, 
1999; Frye and Garber, 2005). In Beck’s study, 
mediation analysis indicated that pain inﬂ  uenced 
fatigue directly as well as indirectly by its effect 
on sleep (Beck et al. 2005). Recently in a cross-
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Table 3. Results of statistical tests. 
Test  p value   p value with    
 with  SEM  spline  regression 
Sobel   0.001   0.001 
Goodman(I)   0.001   0.001476
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sectional study, Xie et al. demonstrated an asso-
ciation between BMI and depression mediated by 
perceived peer isolation in adolescents  (Xie et al. 
2005). Small sample size is another limitation in 
our study. Hence, bootstrapping was employed for 
this issue and possible non-normal distribution.   
In conclusion, the present study found an asso-
ciation between EGFR and cancer cell proliferation 
biomarker Ki-67 in OS patients, and this associa-
tion was carried by the p-AKT. The mediation 
model explained and conﬁ  rmed the EGFR and 
p-AKT pathway and its effect on cancer develop-
ment in OS patients with reasonable satisfaction. 
Thus, mediation model may be a useful approach 
to analyzing pathway information in OS patients. 
The ﬁ  ndings from the study may provide additional 
information for cancer diagnosis and treatment 
with speciﬁ  c targets.
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